Allurar rigakafin Hepatitis A da B
 Allurar rigakafin Hepatitis A da B | |
|---|---|
brand (en)  da vaccine type (en) | |
| Bayanai | |
| Ƙaramin ɓangare na |
hepatitis A vaccine (en) , Hepatitis B vaccine (en) da inactivated vaccine (en) |
| Vaccine for (en) | Cutar hanta A da Hepatitis B |
| Manufacturer (en) |
GSK (en) |
Ana amfani da rigakafin Hepatitis A da B domin samar da kariya daga Hepatitis A da Hepatitis B[1]. Ana ba da shi ta hanyar allura a cikin tsoka.[2]
Ana amfani da shi a yankunan da cutar hepatitis A da B ke da iyaka, ga matafiya, mutanen da ke fama da cutar Hepatitis C ko cutar hanta mai tsanani, da waɗanda ke cikin haɗarin cututtukan da ake samu ta hanyar jima'i.[2]
Allurar rigakafin da aka haɗu tana da aminci da kariya kamar dai an ba ta a matsayin allurar rigakafi ta hepatitis A da B.[2] Gabaɗaya ana jurewa sosai.[3] Sakamakon cututtuka na yau da kullun suna da sauƙi kuma sun haɗa da ja da ciwo a wurin allurar, inda karamin kumfa zai iya bayyana.[3] Jin rauni ko gajiya, ko ciwon kai na iya faruwa.[3] Sauran sakamako masu illa sun haɗa da rashin ƙarfi, ƙanƙara, rash, rauni, zubar da jini mara kyau kamar daga hanci ko gemu, rauni tsoka ko ciwo.[3] Sakamakon cututtuka masu tsanani ba su da yawa kuma sun haɗa da rashin lafiyan da fashewa.[3]
Yana samuwa a ko'ina.[2]
Tsarin gudanarwa
[gyara sashe | gyara masomin]Ana gudanar da allurar rigakafin Twinrix ta yau da kullun ta hanyar allurar intramuscular a yankin deltoid ta amfani da jadawalin allurai daban-daban guda uku a 0, 1, da watanni 6 ([ƙananan lokaci: makonni 4 tsakanin allurai 1 da 2, watanni 5 tsakanin allurai 2 da 3]).[4] A wasu yanayi, ana iya amfani da jadawalin hanzarin sashi na 0, 7 da 21 zuwa 30 kwanaki sannan kuma ana nuna cewa yana da irin wannan inganci kamar jadawalin gargajiya.[5]
Tasiri
[gyara sashe | gyara masomin]Cibiyoyin Kula da Cututtuka da Rigakafin Cututtuka na Amurka (CDC) sun ba da rahoton cewa gwaje-gwajen asibiti sun sami matakan kariya daga Hepatitis A da Hepatitis B wata daya bayan kowane sashi:[6]
- A: 93.8%, 98.8%, 99.9%
- B: 30.8%, 78.2%, 98.5%
Samun sa
[gyara sashe | gyara masomin]Twinrix alama ce da GlaxoSmithKline Biologicals ta ƙera. Cikakken sunan shine allurar rigakafin Hepatitis A da ba a aiki ba da kuma allurar rigakawa ta Hepatitis B (recombinant).[7] Ana ba da Twinrix a kan allurai uku. An kirkiro sunan ne saboda cakuda ne na allurar rigakafi biyu da suka gabata - Havrix, allurar rigar Hepatitis A da ba ta aiki ba, da Engerix-B, allurar Allurar rigakafin Hepatitis B. [ana buƙatar hujja]Twinrix ya fara shiga kasuwa a farkon shekara ta 1997.[8]
A Amurka, Hukumar Abinci da Magunguna (FDA) ta amince da Twinrix ga waɗanda suka kai shekaru 18 da haihuwa.[7] A wasu ƙasashe a waje da Amurka, musamman Kanada da Tarayyar Turai, an san Twinrix da Twinrix Adult ko Ambirix kuma tsarin ilimin yara, wanda ake kira Twinrix Junior ko Twinrix Paediatric, yana samuwa..[9][10][11][12][13][14][15][16] [<span title="This claim has too many footnotes for reading to be smooth. (January 2021)">excessive citations</span>]
Al'umma da al'adu
[gyara sashe | gyara masomin]Tattalin Arziki
[gyara sashe | gyara masomin]Ta hanyar kasancewa haɗuwa yana iya rage farashin gudanarwa kuma ya sami ingantaccen maganin rigakafin.[17]
Sunayen alama
[gyara sashe | gyara masomin]Sunayen alama sun haɗa da Twinrix, Twinrix Junior, Twinrix paediatric, Ambirix,[2] da Bilive.[4]
Manazarta
[gyara sashe | gyara masomin]- ↑ van Damme P (2017). "12. Hepatitis A vaccines". In Vesikari T, van Damme P (eds.). Pediatric Vaccines and Vaccinations: A European Textbook. Switzerland: Springer. p. 107. ISBN 978-3-319-59950-2.
- ↑ 2.0 2.1 2.2 2.3 2.4 "Hepatitis A and B vaccine Uses, Side Effects & Warnings". Drugs.com. Retrieved 27 December 2021.
- ↑ 3.0 3.1 3.2 3.3 3.4 "Hepatitis A and B vaccine Uses, Side Effects & Warnings". Drugs.com. Retrieved 27 December 2021.
- ↑ 4.0 4.1 "Recommended Adult Immunization Schedule for ages 19 years or older, United States, 2019". Centers for Disease Control and Prevention (CDC). 5 February 2019. Retrieved 22 September 2019.
- ↑ "Notice to Readers: FDA Approval of an Alternate Dosing Schedule for a Combined Hepatitis A and B Vaccine (Twinrix)" (PDF). Centers for Disease Control and Prevention (CDC). 12 October 2007. Retrieved 22 September 2019.
- ↑ "FDA approval for a combined hepatitis A and B vaccine" (PDF). MMWR. Morbidity and Mortality Weekly Report. 50 (37): 806–7. September 2001. PMID 11785573.
- ↑ 7.0 7.1 "Twinrix". Food and Drug Administration (FDA). 24 April 2019. Retrieved 22 September 2019.
- ↑ "SB's Twinrix Launched In Its First Market". thepharmaletter.com. 20 January 1997. Retrieved 23 December 2019.
- ↑ "Twinrix Adult Vaccine SmPC". Datapharm. 8 October 2018.
- ↑ "Twinrix Paediatric Vaccine SmPC". Datapharm. 8 October 2018.
- ↑ "Ambirix SmPC". Datapharm. 5 November 2018.
- ↑ "Hepatitis A Vaccine: Canadian Immunization Guide". Public Health Agency of Canada. 2018-03-13. Retrieved 22 September 2019.
- ↑ "Twinrix (720/20)". The Australian Immunisation Handbook. 4 June 2018. Retrieved 22 September 2019.
- ↑ "Twinrix (720/20)". The Australian Immunisation Handbook. August 3, 2021. Retrieved 22 September 2019.
- ↑ "Twinrix Junior (360/10)". The Australian Immunisation Handbook. 4 June 2018. Retrieved 22 September 2019.
- ↑ "Twinrix Junior (360/10)". The Australian Immunisation Handbook. August 3, 2021. Retrieved 22 September 2019.
- ↑ Bakker M, Bunge EM, Marano C, de Ridder M, De Moerlooze L (July 2016). "Immunogenicity, effectiveness and safety of combined hepatitis A and B vaccine: a systematic literature review". Expert Review of Vaccines. 15 (7): 829–851. doi:10.1586/14760584.2016.1150182. PMID 26840060. S2CID 3349582.